Secondary Offering, Appointments, and Clinical Developments - Analyst Notes on HCA, Biogen Idec, WellPoint, AbbVie and Mylan

NEW YORK, May 23, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding HCA Holdings Inc (NYSE: HCA), Biogen Idec Inc (NASDAQ: BIIB), WellPoint Inc (NYSE: WLP), AbbVie Inc (NYSE: ABBV) and Mylan Inc (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2836-100free.

--
HCA Holdings Inc Analyst Notes
On May 19, 2014, HCA Holdings Inc (HCA) announced that some of its stockholders, principally consisting of affiliates of, or funds sponsored by, Bain Capital Partners, LLC and Kohlberg Kravis Roberts & Co. (the Selling Stockholders), plan to sell an underwritten secondary offering of 15 million shares of its common stock, pursuant to the Company's shelf registration statement filed to the Securities and Exchange Commission. HCA informed that all proceeds will be received by the Selling Stockholders. According to the Company, the last sale price of the Company's common stock on May 19, 2014 was $51.51 per share. HCA expects the offering to close on May 23, 2014. The Company added that depending on the closing of the offering, HCA has agreed to repurchase approximately $750 million of additional shares of its common stock from the Selling Stockholders at the net offering price. The full analyst notes on HCA are available to download free of charge at:

http://www.analystsreview.com/2836-HCA-23May2014.pdf

--
Biogen Idec Inc Analyst Notes
On May 12, 2014, Biogen Idec Inc (Biogen Idec) announced that Richard A. Rudick, M.D. has assumed the position of Vice President of Development Sciences of the newly-created Value-Based Medicine Group at the Company and will report to Alfred Sandrock, M.D., Ph.D., Group Senior Vice President and Chief Medical Officer. The Company reported that Dr. Rudick will lead Value-Based Medicine Group to focus on using new technology to develop innovative programs and tools to better understand, measure, and manage the treatment of multiple sclerosis (MS). Biogen Idec informed that Dr. Rudick most recently worked at the Cleveland Clinic as Director of the Mellen Center for Multiple Sclerosis Treatment and Research. The full analyst notes on Biogen Idec are available to download free of charge at:

http://www.analystsreview.com/2836-BIIB-23May2014.pdf

--
WellPoint Inc Analyst Notes
On May 19, 2014, WellPoint Inc's (WellPoint) reported that Dr. Richard Frank, Medical Director for WellPoint's affiliated Medicare products, stated that mammogram should be used to check for breast cancer for older woman aged 50 to 74 at least every two years. He added that depending on their health and doctor's recommendation, women over 74 may want to continue getting a mammogram every two years. Dr. Frank said, "Mammograms aren't perfect, but they are the best tool we have in detecting breast cancer early when it's most treatable. Preventive care mammograms are covered by Medicare at no extra cost and they generally take less than 20 minutes. Considering the prevalence of breast cancer in older women, it's one of the best things they can do for their health." The full analyst notes on WellPoint are available to download free of charge at:

http://www.analystsreview.com/2836-WLP-23May2014.pdf

--
AbbVie Inc Analyst Notes
On May 20, 2014, AbbVie Inc (AbbVie) announced that the U.S. Food and Drug Administration (FDA) has granted HUMIRA® (adalimumab) orphan drug designation for the treatment of a group of rare but serious inflammatory diseases of the eye including non-infectious intermediate, posterior, pan-uveitis, or chronic non-infectious anterior uveitis. The Company added that though HUMIRA® is not yet approved to treat any form of uveitis, the Company is investigating the efficacy and safety of the drug for the treatment of non-infectious uveitis, and added that the clinical program is currently in its Phase III development. Scott Brun, M.D., Vice President, Pharmaceutical Development, AbbVie, said, "Few well characterized treatment options are available for patients suffering from uveitis, and the orphan drug designation recognizes the significant unmet need that exists within this disease." The full analyst notes on AbbVie are available to download free of charge at:

http://www.analystsreview.com/2836-ABBV-23May2014.pdf

--
Mylan Inc Analyst Notes
On May 14, 2014, Mylan Inc (Mylan) announced the launch of Olanzapine Orally Disintegrating Tablets (ODT) in 5 mg, 10 mg, 15 mg, and 20 mg - the generic version of Eli Lilly and the Company's Zyprexa Zydis® Tablets. According to the Company, it has received the final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for the product, indicated for the treatment of schizophrenia or the acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. The full analyst notes on Mylan are available to download free of charge at:

http://www.analystsreview.com/2836-MYL-23May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review